Leveraging on sophisticated deep-learning technology, Visiona MedTech has developed VisionaDR, Hong Kong’s first commercially available retinal image analysis system which comes with robust AI (Artificial Intelligence) capabilities. VisionaDR forms the core engine of Visiona’s fully-automated diabetic retinopathy screening (DRS) platform (“the Platform”), which boosts a friendly UI, cloud-based analytic tools (for big data analysis & mining) and storage (for electronic health records). An independent clinical validation report released by a Hong Kong-based world's top 100 university recommends VisionaDR, with a sensitivity of 98% and a specificity of 95%, is safe for DRS practice in community. Screening procedures: 1. Capture participant's retinal images with a fundus cameras (any brands), 2. upload the images onto the Platform automatic analysis and graded based on International Council of Ophthalmology (ICO) guidelines. 3. a report containing screening results generated in 3 seconds, Health check centers, for example, once equipped with fundus camera, can deploy the Platform to provide professional, reliable and instant DRS service. The Platform enables cost-efficient DRS delivered to the communities via telemedicine/ mobile medicine models.